Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HuNbTROP2-HSA-MMAE
- Development stage
- Preclinical
- Lead developer
- Novamab Biopharmaceuticals
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**HuNbTROP2-HSA-MMAE** is a preclinical TROP2-directed nanobody-drug conjugate developed for **TROP2-positive pancreatic cancer**. It comprises a humanized anti-TROP2 nanobody fused with an anti-human serum albumin nanobody to support systemic exposure, conjugated to the microtubule-disrupting payload monomethyl auristatin E through an MC-VC-PAB protease-cleavable linker with a drug-to-antibody ratio of 1. Following TROP2 binding and tumor-cell internalization, lysosomal processing releases MMAE, causing microtubule disruption and apoptosis associated with caspase-3 and caspase-9 activation. The agent showed potent antitumor activity in TROP2-positive pancreatic cancer cell models and xenografts, including complete tumor eradication at 5 mg/kg in a reported mouse xenograft study.
- Other names
- HuNb TROP2-HSA-MMAE
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on HuNbTROP2-HSA-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HuNbTROP2-HSA-MMAE.